Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer’s, despite trial setback
GLP-1
drugs, which include Ozempic and Wegovy, have become one of the most
closely watched experimental approaches for slowing Alzheimer’s — a
disease with few treatment options.
No comments:
Post a Comment